[{"id":"2974135e-ebdf-4d64-8099-6f751a860dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04590664","created_at":"2021-01-18T21:53:39.246Z","updated_at":"2024-07-02T16:35:17.654Z","phase":"Phase 1/2","brief_title":"Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma","source_id_and_acronym":"NCT04590664","lead_sponsor":"Emory University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Visudyne (verteporfin)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2024-02-26"}]